The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.
General
Each dose is personalized to the individual and compounded by a licensed pharmacy after consultation, taken as a once-weekly self-injection.